Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

A compound represented by formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• ring A is selected from the group consisting of:
• 6-10 membered aryl and 5-10 membered heteroaryl, said heteroaryl containing from 1-4 heteroatoms, 0-2 of which are O or S atoms, and 0-4 of which are N;
• Y is present or absent, and when present, represents O, S, NH or CH2;
• X is present or absent, and when present, represents O or CH2;
• each R1 is H or is selected from the group consisting of:
• (a) halo, OH, CO2R4, SOpR5, CN, NO2 C(O)NR6R7 or NR6R7;
• (b) C1-10alkyl, C(O)C1-6alkyl or OC1-6alkyl, the alkyl portions being optionally substituted with:
• (1) 1-5 halo groups, up to perhalo, and 1-2 groups selected from OH, CO2R4, SOpR5, CN, NO2 C(O)NR6R7, NR6R7 and phenyl optionally substituted with 1-3 halo groups and 1-2 groups selected from:
• OH, C1-3alkyl, haloC1-3alkyl, CN, OC1-3alkyl and OhaloC1-3alkyl;
• (c) a 6-10 membered aryl or aryloxy group, said groups being optionally substituted with 1-3 halo groups and 1-2 groups selected from:
• OH, C1-3alkyl, haloC1-3alkyl, CN, OC1-3alkyl and OhaloC1-3alkyl;
• R2 is C1-10alkyl or aryl optionally substituted with 1-3 groups selected from (a), (b) and (c) above;
• R3 represents CH2CH2CO2R4, CH2CH(OH)CO2R4, CH2CF2CO2R4 or 5-tetrazolyl;
• R4 is H or C1-6alkyl, and
• R5 represents a member selected from the group consisting of:
• C1-10alkyl, Aryl or Ar—C1-10alkyl, said C1-10alkyl, Aryl and Ar—C1-10alkyl being optionally substituted with 1-3 halo groups;
• R6 and R7 each independently represent H or C1-3alkyl,
• R8 is selected from the group consisting of:
• H, OH, C1-3alkyl, haloC1-3alkyl, CN, OC1-3alkyl and OhaloC1-3alkyl, and
• p is 0, 1 or 2.